Pseudomonas Aeruginosa-Specific Bacteriophage Mixture, Live Consisting Of 3 Bacteriophages (Ihma-2121771-1, Ihma-2121771-2, Ihma-2121908-1)

Cystic Fibrosis

BiomX Ltdother_biologicalPhase 2Active

58/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 49/ 100
Competitive Position: 73/ 100

Competitive context

80 Active assets in the Cystic Fibrosis cohort.

Asset / Sponsor	Phase	Rating
Tezacaftor Vertex Pharmaceuticals Incorporated	Phase 4	A
Lumacaftor Hospices Civils de Lyon	Phase 4	BBB
Ivacaftor Meyer Children's Hospital IRCCS	Phase 4	BBB
Liprotamase Anthera Pharmaceuticals	Phase 4	BBB
Elexacaftor Meyer Children's Hospital IRCCS	Phase 4	BBB

View all 50 →

Same molecule, other indications

Pseudomonas Aeruginosa-Specific Bacteriophage Mixture, Live Consisting Of 3 Bacteriophages (Ihma-2121771-1, Ihma-2121771-2, Ihma-2121908-1) is also rated in:

Pseudomonas aeruginosa infectious diseaseActive

Indicative · Phase 2

64 / 100

View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →